AI MARKET SCANNING

Aktis Oncology, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.52%
MAX GAP RECORD +0.76%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $AKTS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 13, 2026 Earnings Release 2026-08-13 (AFTER CLOSE)
+0.76%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
+0.27%
Jan 09, 2026 Earnings Release 2026-01-09 (UNDETERMINED)
+0.00%
Nov 14, 2024 Earnings Release 2024-11-14 (BEFORE OPEN)
+0.00%
May 13, 2024 Earnings Release 2024-05-13 (BEFORE OPEN)
+0.00%
Feb 13, 2024 Earnings Release 2024-02-13 (BEFORE OPEN)
+0.00%
Nov 13, 2023 Earnings Release 2023-11-13 (BEFORE OPEN)
+0.00%
Sep 06, 2023 Earnings Release 2023-09-06 (BEFORE OPEN)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 0.5%
Bullish Gaps (0)
Bearish Gaps (0)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $AKTS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors,…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗